Association between use of antithrombotic medication and hematuria-related complications

Christopher J.D. Wallis, Tristan Juvet, Yuna Lee, Rano Matta, Sender Herschorn, Ronald Kodama, Girish S. Kulkarni, Raj Satkunasivam, William Geerts, Anne McLeod, Steven A. Narod, Robert K. Nam

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

IMPORTANCE: Antithrombotic medications are among the most commonly prescribed medications. OBJECTIVE: To characterize rates of hematuria-related complications among patients taking antithrombotic medications. DESIGN, SETTING, AND PARTICIPANTS: Population-based, retrospective cohort study including all citizens in Ontario, Canada, aged 66 years and older between 2002 and 2014. The final follow-up date was December 31, 2014. EXPOSURES: Receipt of an oral anticoagulant or antiplatelet medication. MAIN OUTCOMES AND MEASURES: Hematuria-related complications, defined as emergency department visit, hospitalization, or a urologic procedure to investigate or manage gross hematuria. RESULTS: Among 2 518 064 patients, 808 897 (mean [SD] age, 72.1 [6.8] years; 428 531 [53%] women) received at least 1 prescription for an antithrombotic agent over the study period. Over a median follow-up of 7.3 years, the rates of hematuria-related complications were 123.95 events per 1000 person-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-years among patients not exposed to these drugs (difference, 43.8; 95% CI, 43.0-44.6; P < .001, and incidence rate ratio [IRR], 1.44; 95% CI, 1.42-1.46). The rates of complications among exposed vs unexposed patients (80.17 events/1000 person-years) were 105.78 for urologic procedures (difference, 33.5; 95% CI, 32.8-34.3; P < .001, and IRR, 1.37; 95% CI, 1.36-1.39), 11.12 for hospitalizations (difference, 5.7; 95% CI, 5.5-5.9; P < .001, and IRR, 2.03; 95% CI, 2.00-2.06), and 7.05 for emergency department visits (difference, 4.5; 95% CI, 4.3-4.7; P < .001, and IRR, 2.80; 95% CI, 2.74-2.86). Compared with patients who were unexposed to thrombotic agents, the rates of hematuria-related complications were 191.61 events per 1000 person-years (difference, 117.3; 95% CI, 112.8-121.8) for those exposed to both an anticoagulant and antiplatelet agent (IRR, 10.48; 95% CI, 8.16-13.45), 140.92 (difference, 57.7; 95% CI, 56.9-58.4) for those exposed to anticoagulants (IRR, 1.55; 95% CI, 1.52-1.59), and 110.72 (difference, 26.5; 95% CI, 25.9-27.0) for those exposed to antiplatelet agents (IRR, 1.31; 95% CI, 1.29-1.33). Patients exposed to antithrombotic agents, compared with patients not exposed to these drugs, were more likely to be diagnosed as having bladder cancer within 6 months (0.70% vs 0.38%; odds ratio, 1.85; 95% CI, 1.79-1.92). CONCLUSIONS AND RELEVANCE: Among older adults in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications, was significantly associated with higher rates of hematuria-related complications (including emergency department visits, hospitalizations, and urologic procedures to manage gross hematuria).

Original languageEnglish (US)
Pages (from-to)1260-1271
Number of pages12
JournalJAMA: The Journal of the American Medical Association
Volume318
Issue number13
DOIs
StatePublished - Oct 3 2017

Keywords

  • Journal Article
  • Research Support, Non-U.S. Gov't

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Association between use of antithrombotic medication and hematuria-related complications'. Together they form a unique fingerprint.

Cite this